Feature | Heart Valve Technology | June 09, 2020

SMT Hydra TAVR System Receives European CE Mark Approval

Indian-made device used to treat transcatheter aortic stenosis

SMT (Sahajanand Medical Technology Private Ltd.), a leading medical device company of India focused on cardiology, announced it Hydra transcatheter aortic valve replacement (TAVR) device received European CE mark approval. It is indicated for the treatment of patients diagnosed with aortic stenosis. #SMT #HYDRA #TAVR

The self-expanding SMT Hydra transcatheter aortic valve replacement (TAVR) device.


June 9, 2020 — SMT (Sahajanand Medical Technology Private Ltd.), a leading medical device company in India focused on cardiology, announced its Hydra transcatheter aortic valve replacement (TAVR) device received European CE mark approval. It is indicated for the treatment of patients diagnosed with aortic stenosis. 

This regulatory approval paves the path for SMT to tap into a fast growing $3.8 billion global TAVR market. The Indian company has been been working to develop transcatheter device technologies that are on par with U.S. and European vendors, and has already show its technologies in comparison trials are as good as, or better, than some of the name brands in the international market. The company has been highlighted in many sessions and some late-breaking studies at the annual Transcatheter Cardiovascular Therapeutics (TCT) meetings.

The Hydra aortic valve is a self-expandable nitinol-based supra annular aortic system with a mechanism for recapturing of the valve during deployment. This unique property of the device helps in precise placement of the valve and ensures orthotopic deployment. Hydra is available in three sizes — 22, 26 and 30 mm — and is selected depending upon the diameter of the native annulus from 18-27 mm.

Clinical data from the Genesis Trial conducted in India and presented at the India Valves Conference 2019 held in Chennai, confirm the system’s ability to eliminate significant aortic regurgitation. In another CE clinical study conducted in Europe, the system also demonstrated a strong safety profile on 110 patients enrolled till February 2020.

The benefits of the Hydra Aortic Valve System are enabled by its frame design and repositionable and retrievable delivery system. The non-flared inflow section of the frame and supra-annular valve leaflet design ensures better aortic valvular area in smaller annuli and in valve-in-valve settings. The frame features 3 tentacles or antenna for better anchorage and larger cells (10mm) which give better access for the future coronary interventional procedures if required. The delivery cable is highly flexible and 18 French compatible, and the device can be recaptured, repositioned and retrieved even after 85-90 percent of deployment of the valve thereby eliminating to almost zero complications of deployment of TAVR device. The precise orthotopic supra-annular placement, positioning and deployment is facilitated by this unique property of re-capturability of Hydra. 

“Hydra is a novel transcatheter heart valve for treatment of patients with severe aortic stenosis," said Prof. Lars Sondegaard, M.D., principal investigator of the trial, Rigshospitalet, Copenhagen University Hospital, Copenhagen. "Features that favor this self-expanding technology with supra-annular position of the leaflet include small size delivery system allowing transfemoral access despite small access vessels, flexible system favoring challenging anatomy such as tortuous anatomy and horizontal aorta, large efficient orifice area of the valve, and low rate of paravalvular leakage and pacemaker. During the trials in Asia, Europe and New Zealand more than 200 patients have benefited from the Hydra valve and I am certain it will fill an important space in the near future.”

With a CE certification, SMT looks forward in expanding its structural heart business across Europe. ”The hydra valve has been designed to make the TAVR procedure user friendly and to simplify the procedure with the lowest profile delivery system and a valve where the function of the valve can be observed before the final release," explained Founder and chief innovator of Hydra Valve, Swaminathan Jayaraman. "The two set of markers on the Valve is a unique design which provides good visual ability to position the valve and takes the variability out of the difficulties associated with positioning in difficult anatomy.”  

SMT has established a regional headquarter in Ireland to better serve its customers in Europe and Middle East. In addition to R&D and manufacturing center in Ireland, SMT has established direct presence and local offices in most of the large markets in Europe. 

The SMT Cruz stent.SMT launched Supraflex Cruz DES last year in Europe and said the release has been met with success in the market. Now with Hydra, SMT said it will be able to better serve its customers and patients across Europe. 

SMT is a global medical device company committed to make advanced medical technologies accessible to everyone around the world. With presence in 75 countries, SMT has achieved recognitions from the Indian Ministry of Health Sciences and Technologies for its tremendous contributions in the field of coronary healthcare. SMT also pioneered the introduction of biodegradable polymer in the cardiovascular segment. 

For more information: SMTpl.com

 

Related SMT Cardiology Device Content:

Innovations in Cardiovascular Disease Treatment and the Rising Demand for Stents 

Supraflex Drug-Eluting Stent Superior to Xience in Two-Year Target Vessel Failure

Coronary Stent Market Characterized by New Drug-eluting Stents
 

Related Content

News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
News | Cath Lab

December 14, 2021 — RSIP Vision, a medical imaging company applying advanced artificial intelligence (AI) and computer ...

Home December 14, 2021
Home
Feature | Cath Lab

November 15, 2021 — RealView Imaging Ltd. recently received FDA 510(k) clearance for its Holoscope-i holographic system ...

Home November 15, 2021
Home
Subscribe Now